Pectic Galactan Polysaccharide‐Based Gene Delivery System for Targeting Neuroinflammation
Authors:
- 10 June 2021
- journal article
- research article
- Published by Wiley in Advanced Functional Materials
- Vol. 31 (44) , 2100643
Abstract
Treating neuroinflammation‐related injuries and disorders through manipulation of neuroinflammation functions is being heralded as a new therapeutic strategy. In this study, a novel pectic galactan (PG) polysaccharide based gene therapy approach is developed for targeting reactive gliosis in neuroinflammation. Galectin‐3 (Gal‐3) is a cell protein with a high affinity to β‐galactoside sugars and is highly expressed in reactive gliosis. Since PG carries galactans, it can target reactive gliosis via specific carbohydrate interaction between galactan and Gal‐3 on the cell membrane, and therefore can be utilized as a carrier for delivering genes to these cells. The carrier is synthesized by modifying quaternary ammonium groups on the PG. The resulting quaternized PG (QPG) is found to form complexes with plasmid DNA with a mean diameter of 100 nm and have the characteristics required for targeted gene therapy. The complexes efficiently condense large amounts of plasmid per particle and successfully bind to Gal‐3. The in vivo study shows that the complexes are biocompatible and safe for administration and can selectively transfect reactive glial cells of an induced cortical lesion. The results confirm that this PG‐based delivery system is a promising platform for targeting Gal‐3 overexpressing neuroinflammation cells for treating neuroinflammation‐related injuries and neurodegenerative diseases.Keywords
Funding Information
- United States - Israel Binational Science Foundation (2009178)
This publication has 95 references indexed in Scilit:
- Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson’s DiseaseFrontiers in Aging Neuroscience, 2017
- Microglia in the TBI brain: The good, the bad, and the dysregulatedExperimental Neurology, 2016
- Chronic Neurodegeneration After Traumatic Brain Injury: Alzheimer Disease, Chronic Traumatic Encephalopathy, or Persistent Neuroinflammation?Neurotherapeutics, 2015
- Targeting Microglial Activation in Stroke Therapy: Pharmacological Tools and Gender EffectsCurrent Medicinal Chemistry, 2014
- Reactive Gliosis and the Multicellular Response to CNS Damage and DiseaseNeuron, 2014
- Live imaging of astrocyte responses to acute injury reveals selective juxtavascular proliferationNature Neuroscience, 2013
- The neuroinflammatory response in humans after traumatic brain injuryNeuropathology and Applied Neurobiology, 2012
- Microglial Activation and Antioxidant Responses Induced by the Parkinson’s Disease Protein α-SynucleinJournal of Neuroimmune Pharmacology, 2012
- Microglia Activation and Anti-inflammatory Regulation in Alzheimer’s DiseaseMolecular Neurobiology, 2010
- The role of microglia and macrophages in the pathophysiology of the CNSProgress in Neurobiology, 1999